Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Go back to Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)| (NASDAQ: PRTC) | Delayed: 17.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.42 | 52 Week High | $ | |||
| Open | $17.42 | 52 Week Low | $ | |||
| Day High | $17.42 | P/E | N/A | |||
| Day Low | $17.42 | EPS | $ | |||
| Volume | 2,259 | |||||
